



# ALPHAЕON™

## **ALPHAЕON BEGINS PHASE III STUDY FOR ITS NEUROTOXIN, EVOSYAL**

**IRVINE, Calif., January 22, 2015**, - ALPHAЕON® Corporation announced today that the U.S. Food and Drug Administration (FDA) agreed to the protocol for its phase III clinical study of EVOSYAL™, to treat glabellar lines. ALPHAЕON acquired the exclusive U.S. and certain international distribution rights to EVOSYAL, a Botulinum toxin Type A neuromodulator, as part of its acquisition of Evolus Inc. In the last 12 months, ALPHAЕON has submitted its investigational new drug application for EVOSYAL and completed enrollment in its phase II study.

“We are looking forward to initiating this pivotal study in January with our cohort of experienced U.S. investigators,” said Rui Avelar, MD, ALPHAЕON Chief Medical Officer.

“The agreement with the FDA on our phase III pivotal study protocol marks another key milestone on the execution of our neuromodulator development plan,” said Chris Marmo, Ph.D. President of ALPHAЕON Beauty.

ALPHAЕON began enrollment of its phase III study on January 14th, 2015.

### **About ALPHAЕON Corporation**

ALPHAЕON Corporation, a subsidiary of Strathspey Crown Holdings, LLC, is a lifestyle healthcare company committed to working with board-certified physicians to provide innovative products and services that promote patient wellness, beauty and performance. For more information, please visit [www.alphaeon.com](http://www.alphaeon.com).

### **About Strathspey Crown**

Strathspey Crown is a leading firm focused in lifestyle healthcare. Strathspey Crown uniquely partners with board certified physician specialists to bring to market innovative technologies and services in the self-pay sector. The firm is founded with physician investors across key medical specialties including: plastic surgery, ophthalmology, dermatology, orthopedics and cosmetic dentistry. For more information, please visit [www.strathspeycrown.com](http://www.strathspeycrown.com).

### **PRESS CONTACT:**

Jenna Mons, Vice President of Marketing and Communications  
Tel: 949-284-4523  
Email: [press@alphaeon.com](mailto:press@alphaeon.com)

ALPHAЕON® is a registered trademark of ALPHAЕON Corporation  
EVOSYAL™ is a trademark of ALPHAЕON Corporation



ALPHAEON™

# # #